We are pleased to announce that our Yokohama Japan site is officially listed on the Japanese Industrial Standard (JIS) Q 2101 Self-Declaration Registry, operated by the Forum for Innovative Regenerative Medicine (FIRM). This registry publishes organizations that have declared conformance to JIS Q 2101, Japan’s standard for cell therapy manufacturing management.
The standard was first published in February of 2025 and as of July 1, 2025, Minaris Advanced Therapies became the first company in Japan to be listed. JIS Q 2101 is a Japanese Industrial Standard that defines a management framework for the consistent and reliable manufacturing of cell-processed products—products derived from cultured and processed human or animal cells. The standard outlines methods for establishing and continuously improving manufacturing processes to ensure product quality and safety in the fields of regenerative medicine and biotechnology.
This declaration demonstrates that the manufacturing systems at our Yokohama site have been developed and operated in accordance with the quality management framework defined by JIS Q 2101. Our listing on the registry serves as a public statement of our commitment to enhancing continued excellence in manufacturing practices.
If you are interested in visiting our Yokohama site or learning more about our capabilities, please contact us.